Gossamer Bio, Inc. (GOSS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 12, 2024, announces the issuance of a press release detailing the financial results for the quarter ended June 30, 2024. The registrant is Gossamer Bio, Inc., a Delaware corporation headquartered in San Diego, California, with common stock trading on the Nasdaq Global Select Market under the symbol "GOSS."
Key Financial Metrics
The provided filing text serves as a notification of the results and does not contain specific numerical data. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. These figures are contained within the attached press release (Exhibit 99.1), which is not included in the source text provided.
Material Changes
No material changes versus the prior comparable period are detailed in this specific document. The filing references the attached press release for the full operational and financial comparison.
Guidance, Outlook, and Risks
The filing does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It explicitly states that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2024) for actual Q2 2024 financial figures.
- Verify the specific revenue, net loss, and cash burn rate reported in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the company's cash position and runway as disclosed in the detailed financial statements.